PHARMA
PHARMAPharmaceutical Hydrogenation Membrane in France
Catalytic hydrogenation is a critical step in active pharmaceutical ingredient (API) synthesis. France has committed EUR 7.
Market Context
FrancePolicy
H₂ Target
Cities
Industries
Ultra-Clean Hydrogen Source
Electrolytic hydrogen from water splitting is inherently free of carbon monoxide, sulfur, and hydrocarbon impurities that can poison precious metal hydrogenation catalysts used in API manufacturing.
GMP-Compatible On-Site Generation
On-site electrolysis provides a controlled, traceable hydrogen source that simplifies GMP documentation and qualification versus multi-sourced delivered gas.
Batch-Flexible Operation
Pharmaceutical manufacturing operates in batches. IONZERA's high wettability supports start-stop operation, generating hydrogen only when hydrogenation reactors require it.
Pharmaceutical Hydrogenation in France’s Hydrogen Market
France has committed EUR 7.2 billion to its hydrogen strategy, targeting 6.5 GW of electrolyser capacity by 2030. With strong nuclear baseload power and growing renewable capacity, France has a cost-competitive electricity base for green hydrogen production. Industrial hydrogen demand from refineries and chemical plants in Lyon, Marseille, and the Rhone valley drives near-term electrolysis deployment.
IONZERA's 3x lower resistance improves electrolyser efficiency, complementing France's low-carbon electricity advantage. For French OEMs and project developers, IONZERA offers diversified sourcing with competitive pricing from Indian manufacturing.
Lower Resistance
Thinner Profile
PERFORMANCE ADVANTAGE
Why IONZERA for Pharmaceutical Hydrogenation in France
Electrolytic hydrogen from water splitting is inherently free of carbon monoxide, sulfur, and hydrocarbon impurities that can poison precious metal hydrogenation catalysts used in API manufacturing.
Shipping & Logistics
Air freight from India in 5-7 business days. Major delivery points in Lyon and Marseille industrial corridors.
Area Resistance
3x LOWERThickness
20% THINNERFrequently Asked Questions
Why choose IONZERA for pharmaceutical hydrogenation in France?
IONZERA delivers 3x lower ionic resistance than Zirfon, making it ideal for pharmaceutical hydrogenation applications in France. IONZERA's 3x lower resistance improves electrolyser efficiency, complementing France's low-carbon electricity advantage.
How does IONZERA fit France's hydrogen decarbonization strategy?
IONZERA's 3x lower area resistance reduces the electricity consumption per kg of hydrogen, improving the economics of electrolysis powered by France's nuclear and renewable electricity mix. This directly supports France's 6.5 GW electrolyser deployment target.
Can IONZERA be delivered to French industrial hydrogen projects?
Yes. G-Hexa ships IONZERA globally via air freight (5-7 days to France) or sea freight for volume orders. Technical support and sample requests are handled directly by the G-Hexa team.
EXPLORE MORE
Request Pharmaceutical Hydrogenation Samples for France
Contact G-Hexa for IONZERA pharmaceutical hydrogenation membrane samples, technical specifications, and volume pricing for France-based projects.
Request Sample